Carolinas Medical Center Investigational Drug Services — Charlotte, North Carolina

Carolinas Medical Center Investigational Drug Services is a clinical research site located in Charlotte, North Carolina, United States 28204.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Carolinas Medical Center Investigational Drug Services has participated in 2 clinical trials with 2 currently active.

Therapeutic areas: HER2-positive Breast Cancer, Urothelial Carcinoma.

Sponsors: Seagen, a wholly owned subsidiary of Pfizer.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Charlotte

Browse all research sites in North Carolina · View every site in Charlotte

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Carolinas Medical Center Investigational Drug Services?

Carolinas Medical Center Investigational Drug Services has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Carolinas Medical Center Investigational Drug Services conducted?

Carolinas Medical Center Investigational Drug Services has 2 clinical trials on record, with 2 currently active. Their work covers HER2-positive Breast Cancer, Urothelial Carcinoma.

Is Carolinas Medical Center Investigational Drug Services accredited by Crixeo Clinical Trials?

Carolinas Medical Center Investigational Drug Services has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Carolinas Medical Center Investigational Drug Services?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.